References
- Borghesi A, Golemi S, Carapella N, et al. Lombardy, Northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation. Infect Dis. 2021;53(5):370–375.
- Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. [cited 2021 Dec 24]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- Gunadi Hakim MS, Wibawa H, Setiawaty V, et al. Is the infection of the SARS-CoV-2 Delta variant associated with the outcomes of COVID-19 patients? Front Med. 2021;8:780611.
- Hussey H, Davies MA, Heekes A, et al. Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp target delay as a proxy. medRxiv. 2021;2021.10.23.21265412.
- Edward PR, Lorenzo-Redondo R, Reyna ME, et al. Severity of illness caused by severe acute respiratory syndrome coronavirus 2 variants of concern in children: a single-center retrospective cohort study. Preprint. medRxiv. 2021;2021.10.23.21265402.
- Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (alpha), B.1.315 (beta), and B.1.617.2 (Delta). Clin Infect Dis. 2021:ciab721.
- Butt AA, Dargham SR, Chemaitelly H, et al. Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs beta variant in Qatar. JAMA Intern Med. 2022;182(2):197.
- Li B, Deng A, Li K, et al. Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant. Nat Commun. 2022;13(1):460.
- Kow CS, Ramachandram DS, Hasan SS. The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Immunopharmacol Immunotoxicol. 2022;44(1):28–34.